The risk of cardiovascular side effects with anti-anginal drugs

References

• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–e360.
   PubMed Web of Science ®Google Scholar
• Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood). 2007;26(1):38–48.
   PubMed Web of Science ®Google Scholar
• Task Force M, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.
   PubMed Web of Science ®Google Scholar
• Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44–e164.
   PubMed Web of Science ®Google Scholar
• Mancini GB, Gosselin G, Chow B, et al. Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. Can J Cardiol. 2014;30(8):837–849.
   PubMed Web of Science ®Google Scholar
• Thadani U. Chronic stable angina pectoris, ed. D.M.a.C. M. London: Harcourt Publishers; 2009.
   Google Scholar
• Thadani U. Current medical management of chronic stable angina. J Cardiovasc Pharmacol Ther. 2004; 9(Suppl 1):S11–S29; quiz S98–S99.
   PubMedGoogle Scholar
• Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation. 1983;68(5):939–950.
   PubMed Web of Science ®Google Scholar
• Group BDS, Frye RL, August P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–2515.
   PubMed Web of Science ®Google Scholar
• Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–1516.
   PubMed Web of Science ®Google Scholar
• Bonchek LI. Twenty-two years and it just keeps going, going, going: the veterans affairs cooperative study of coronary artery bypass surgery for stable angina. Heart Surg Forum. 1999;2(4):287–289.
   PubMedGoogle Scholar
• Gupta AK, Winchester D, Pepine CJ. Antagonist molecules in the treatment of angina. Expert Opin Pharmacother. 2013;14(17):2323–2342.
   PubMed Web of Science ®Google Scholar
• Asirvatham S, Sebastian C, Thadani U. Choosing the most appropriate treatment for stable angina. Safety considerations. Drug Saf. 1998;19(1):23–44.
   PubMed Web of Science ®Google Scholar
• Thadani U. Selection of optimal therapy for chronic stable angina. Curr Treat Options Cardiovasc Med. 2006;8(1):23–35.
   PubMedGoogle Scholar
• G.S. Inc. Ranolazine prescribing information. 2016 Jan.
   Google Scholar
• Vitetta KAOBL. The potential role of herbal medicines in the treatment of chronic stable angina pectoris: a review of key herbs, and as illustration, exploration of the Chinese herbal medicine approach. Botanics. 2013;3:1–17.
   Google Scholar
• Cheng TO. Cardiovascular effects of danshen. Int J Cardiol. 2007;121(1):9–22.
   PubMed Web of Science ®Google Scholar
• Jia Y, Zhang S, Huang F, et al. Could ginseng-based medicines be better than nitrates in treating ischemic heart disease? A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2012;20(3):155–166.
   PubMed Web of Science ®Google Scholar
• Thadani U, Opie LH. Nitrates. In: Opie LH, editor. Drugs for the heart; Philadelphia, PA: W.B. Saunders; 1995.
   Google Scholar
• Munzel T, Daiber A, Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation. 2011;123(19):2132–2144.
   PubMed Web of Science ®Google Scholar
• Opie LH, Gersh BJ. Drugs for the heart. 8th ed. Philadelphia (PA): Elsevier Saunders; 2013. xiii, 573 p.
   Google Scholar
• Thadani U. Challenges with nitrate therapy and nitrate tolerance: prevalence, prevention, and clinical relevance. Am J Cardiovasc Drugs. 2014;14(4):287–301.
   PubMed Web of Science ®Google Scholar
• Thadani U, Wittig T. A randomized, double-blind, placebo-controlled, crossover, dose-ranging multicenter study to determine the effect of sublingual nitroglycerin spray on exercise capacity in patients with chronic stable angina. Clin Med Insights Cardiol. 2012;6:87–95.
   PubMedGoogle Scholar
• Thadani U, Lipicky RJ. Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther. 1994;8(4):611–623.
   PubMed Web of Science ®Google Scholar
• Thadani U, Fung HL, Darke AC, et al. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy. Am J Cardiol. 1982;49(2):411–419.
   PubMed Web of Science ®Google Scholar
• Thadani U, Lipicky RJ. Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther. 1994;8(4):625–633.
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol. 1993;72(17):1249–1256.
   PubMed Web of Science ®Google Scholar
• Parker JO, Farrell B, Lahey KA, et al. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med. 1987;316(23):1440–1444.
   PubMed Web of Science ®Google Scholar
• Bassan MM. The daylong pattern of the antianginal effect of long-term three times daily administered isosorbide dinitrate. J Am Coll Cardiol. 1990;16(4):936–940.
   PubMed Web of Science ®Google Scholar
• Thadani U, Rodgers T. Side effects of using nitrates to treat angina. Expert Opin Drug Saf. 2006;5(5):667–674.
   PubMed Web of Science ®Google Scholar
• Palaniswamy C, Aronow WS. Treatment of stable angina pectoris. Am J Ther. 2011;18(5):e138–e152.
   Google Scholar
• Acute and chronic antianginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin. Steering Committee, transdermal nitroglycerin cooperative study. Am J Cardiol. 1991;68(13):1263–1273.
   PubMed Web of Science ®Google Scholar
• Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol. 2003;92(9A):9M–18M.
   PubMed Web of Science ®Google Scholar
• Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation. 2004;110(19):3149–3155.
   PubMed Web of Science ®Google Scholar
• Mehvar R, Brocks DR. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci. 2001;4(2):185–200.
   PubMed Web of Science ®Google Scholar
• Husted SE, Ohman EM. Pharmacological and emerging therapies in the treatment of chronic angina. Lancet. 2015;386(9994):691–701.
   PubMed Web of Science ®Google Scholar
• McDevitt DG. Clinical significance of cardioselectivity state-of-the-art. Drugs. 1983;25(Supplement 2):219–226.
   Google Scholar
• Woods PB, Robinson ML. An investigation of the comparative liposolubilities of beta-adrenoceptor blocking agents. J Pharm Pharmacol. 1981;33(3):172–173.
   PubMed Web of Science ®Google Scholar
• Coltart DJ, Meldrum SJ, Hamer J. The effect of propranolol on the human and canine transmembrane action potential. Br J Pharmacol. 1970;40(1):148P–149P.
   Google Scholar
• Cruickshank JM. Measurement and cardiovascular relevance of partial agonist activity (PAA) involving beta 1- and beta 2-adrenoceptors. Pharmacol Ther. 1990;46(2):199–242.
   PubMed Web of Science ®Google Scholar
• Prichard BN. Beta-blocking agents with vasodilating action. J Cardiovasc Pharmacol. 1992;19(Suppl 1):S1–4.
   Google Scholar
• Prichard BN, Owens CW. Mode of action of beta-adrenergic blocking drugs in hypertension. Clin Physiol Biochem. 1990;8(Suppl 2):1–10.
   PubMedGoogle Scholar
• Thadani U, Davidson C, Singleton W, et al. Comparison of the immediate effects of five beta-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris. N Engl J Med. 1979;300(14):750–755.
   PubMed Web of Science ®Google Scholar
• Thadani U, Davidson C, Singleton W, et al. Comparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris. Am J Med. 1980;68(2):243–250.
   PubMed Web of Science ®Google Scholar
• Opie LH, Sonnenblick EH, Freshman W, et al. Beta blockers. In: Opie LH, editor. Drugs for the heart. Philadelphia (PA): W.B. Saunders; 1995.
   Google Scholar
• Hamer J, Grandjean T, Melendez L, et al. Effect of propranolol (inderal) on exercise tolerance in angina pectoris. Br Heart J. 1966;28(3):414–418.
   PubMedGoogle Scholar
• Krepp HP. Evaluation of the antianginal and anti-ischemic efficacy of slow-release isosorbide-5-mononitrate capsules, bupranolol and their combination, in patients with chronic stable angina pectoris. Cardiology. 1991;79(Suppl 2):14–18.
   PubMed Web of Science ®Google Scholar
• Rehnqvist N, Hjemdahl P, Billing E, et al. Treatment of stable angina pectoris with calcium antagonists and beta-blockers. The APSIS study. Angina prognosis study in Stockholm. Cardiologia. 1995;40(12 Suppl 1):301.
   PubMedGoogle Scholar
• Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) study. J Am Coll Cardiol. 1996;27(2):311–316.
   PubMed Web of Science ®Google Scholar
• Waysbort J, Meshulam N, Brunner D. Isosorbide-5-mononitrate and atenolol in the treatment of stable exertional angina. Cardiology. 1991;79(Suppl 2):19–26.
   PubMed Web of Science ®Google Scholar
• Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011. β-adrenoreceptor blockers.
   Google Scholar
• Lee HY, Baek SH. Optimal use of beta-blockers for congestive heart failure. Circ J. 2016;80(3):565–571.
   PubMed Web of Science ®Google Scholar
• Remme WJ, McMurray JJ, Hobbs FD, et al. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Eur Heart J. 2008;29(14):1739–1752.
   PubMed Web of Science ®Google Scholar
• Cordero A, Bertomeu-Gonzalez V, Mazon P, et al. Differential effect of beta-blockers for heart rate control in coronary artery disease. Clin Cardiol. 2011;34(12):748–754.
   PubMed Web of Science ®Google Scholar
• Wikstrand J, Berglund G. Antihypertensive treatment with beta-blockers in patients aged over 65. Br Med J (Clin Res Ed). 1982;285(6345):850.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Koch-Weser J. Clinical toxicity of propranolol and practolol: a report from the Boston collaborative drug surveillance program. In: Avery GS, editor. Cardiovascualr drugs. Vol. 2. Sydnea: Adis Press; 1977.
   Google Scholar
• Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med. 1991;151(9):1769–1776.
   PubMedGoogle Scholar
• Van den Ven LL, Spanjaard JN, De Jongste MJ, et al. Safety of beta-blocker therapy with and without thrombolysis: a comparison of bisoprolol and atenolol in acute myocardial infarction. Curr Ther Res. 1996;57(5):313–326.
   Web of Science ®Google Scholar
• Rubin PC, Butters L, Clark DM, et al. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet. 1983;1(8322):431–434.
   PubMed Web of Science ®Google Scholar
• Brest AN. Hemodynamic and cardiac effects of clonidine. J Cardiovasc Pharmacol. 1980;2(Suppl 1):S39–S46.
   PubMedGoogle Scholar
• Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med. 1999;341(19):1447–1457.
   PubMed Web of Science ®Google Scholar
• Soward AL, Vanhaleweyk GL, Serruys PW. The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review. Drugs. 1986;32(1):66–101.
   PubMed Web of Science ®Google Scholar
• Reid JL, Meredith PA, Donnelly R, et al. Pharmacokinetics of calcium antagonists. J Cardiovasc Pharmacol. 1988;12(Suppl 7):S22–6.
   Google Scholar
• Singh BN, Ellrodt G, Peter CT. Verapamil: a review of its pharmacological properties and therapeutic use. Drugs. 1978;15(3):169–197.
   PubMed Web of Science ®Google Scholar
• Chaffman M, Brogden RN. Diltiazem. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1985;29(5):387–454.
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Hossack K, Mehta JL, et al. Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial. Am Heart J. 1995;129(3):527–535.
   PubMed Web of Science ®Google Scholar
• Glasser SP, West TW. Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris. Am J Cardiol. 1988;62(9):518–522.
   PubMed Web of Science ®Google Scholar
• Antman E, Muller J, Goldberg S, et al. Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med. 1980;302(23):1269–1273.
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Feldman RL, Whittle J, et al. Effect of diltiazem in patients with variant angina: a randomized double-blind trial. Am Heart J. 1981;101(6):719–725.
   PubMed Web of Science ®Google Scholar
• Krebs R. Adverse reactions with calcium antagonists. Hypertension. 1983;5(4 Pt 2):II125–II129.
   Google Scholar
• Nicorandil for angina. Drug Ther Bull. 1995;33(12):89–92.
   PubMedGoogle Scholar
• Camm AJ, Maltz MB. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. Am J Cardiol. 1989;63(21):61J-–65J.
   Web of Science ®Google Scholar
• IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002;359(9314):1269–1275.
   PubMed Web of Science ®Google Scholar
• Rajaratnam R, Brieger DB, Hawkins R, et al. Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris. Am J Cardiol. 1999;83(7):1120–1124, A9.
   PubMed Web of Science ®Google Scholar
• Thadani U. Can nicorandil treat angina pectoris effectively? Nat Clin Pract Cardiovasc Med. 2005;2(4):186–187.
   PubMedGoogle Scholar
• Manolis AJ, Poulimenos LE, Ambrosio G, et al. Medical treatment of stable angina: a tailored therapeutic approach. Int J Cardiol. 2016;220:445–453.
   PubMed Web of Science ®Google Scholar
• McClellan KJ, Plosker GL. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions. Drugs. 1999;58(1):143–157.
   PubMed Web of Science ®Google Scholar
• Onay-Besikci A, Ozkan SA. Trimetazidine revisited: a comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine. Cardiovasc Ther. 2008;26(2):147–165.
   PubMed Web of Science ®Google Scholar
• Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J. 2001;22(24):2267–2274.
   PubMed Web of Science ®Google Scholar
• Thadani U. Modified-release formulation of trimetazidine for exceptional control of angina pectoris: fact or fiction. Am J Cardiovasc Drugs. 2005;5(5):331–334.
   PubMedGoogle Scholar
• Vitale C, Spoletini I, Malorni W, et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina–the VASCO-angina study. Int J Cardiol. 2013;168(2):1078–1081.
   PubMed Web of Science ®Google Scholar
• Peng S, Zhao M, Wan J, et al. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol. 2014;177(3):780–785.
   PubMed Web of Science ®Google Scholar
• Sellier P, Broustet JP. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am J Cardiovasc Drugs. 2003;3(5):361–369.
   PubMedGoogle Scholar
• Dalla-Volta S, Maraglino G, Della-Valentina P, et al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther. 1990;4(Suppl 4):853–859.
   PubMed Web of Science ®Google Scholar
• Reversible parkinsonism linked to trimetazidine (continued). Prescrire Int. 2006;15(84):136.
   PubMedGoogle Scholar
• Marti Masso JF, Marti I, Carrera N, et al. Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie. 2005;60(4):419–422.
   PubMed Web of Science ®Google Scholar
• Masmoudi K, Masson H, Gras V, et al. Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases. Fundam Clin Pharmacol. 2012;26(2):198–203.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European Medicines Agency recommends restricting use of trimetazidine-containing medicines. 2012 Jun 22.
   Google Scholar
• Cocco G, Rousseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol. 1992;20(1):131–138.
   PubMed Web of Science ®Google Scholar
• Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92(Suppl 4):iv6–iv14.
   PubMedGoogle Scholar
• Codolosa JN, Acharjee S, Figueredo VM. Update on ranolazine in the management of angina. Vasc Health Risk Manag. 2014;10:353–362.
   PubMedGoogle Scholar
• Gennari M, Gambini E, Bassetti B, et al. Emerging treatment options for refractory angina pectoris: ranolazine, shock wave treatment, and cell-based therapies. Rev Cardiovasc Med. 2014;15(1):31–37.
   PubMed Web of Science ®Google Scholar
• Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566–575.
   PubMed Web of Science ®Google Scholar
• Sendon JL, Lee S, Cheng ML, et al. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial. Eur J Prev Cardiol. 2012;19(5):952–959.
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Arnold SV, Spertus JA, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013;61(20):2038–2045.
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375–1382.
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309–316.
   PubMed Web of Science ®Google Scholar
• Rousseau MF, Pouleur H, Cocco G, et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95(3):311–316.
   PubMed Web of Science ®Google Scholar
• Thadani U, Ezekowitz M, Fenney L, et al. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine study group. Circulation. 1994;90(2):726–734.
   PubMed Web of Science ®Google Scholar
• Alexander KP, Weisz G, Prather K, et al. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) trial. Circulation. 2016;133(1):39–47.
   PubMed Web of Science ®Google Scholar
• Thadani U. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal. Expert Opin Pharmacother. 2012;13(17):2555–2563.
   PubMed Web of Science ®Google Scholar
• Gutierrez JA, Karwatowska-Prokopczuk E, Murphy SA, et al. Effects of ranolazine in patients with chronic angina in patients with and without percutaneous coronary intervention for acute coronary syndrome: observations from the MERLIN-TIMI 36 trial. Clin Cardiol. 2015;38(8):469–475.
   PubMed Web of Science ®Google Scholar
• FDA. FDA Drug Safety Communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Rockwell (MD): FDA; 2011.
   Google Scholar
• Anderson JR, Nawarskas JJ. Ranolazine. A metabolic modulator for the treatment of chronic stable angina. Cardiol Rev. 2005;13(4):202–210.
   PubMedGoogle Scholar
• Baruscotti M, Bucchi A, Difrancesco D. Physiology and pharmacology of the cardiac pacemaker (“funny”) current. Pharmacol Ther. 2005;107(1):59–79.
   PubMed Web of Science ®Google Scholar
• Ferrari R, Ceconi C. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease. Expert Rev Cardiovasc Ther. 2011;9(8):959–973.
   PubMedGoogle Scholar
• Brown H, Difrancesco D. Voltage-clamp investigations of membrane currents underlying pace-maker activity in rabbit sino-atrial node. J Physiol. 1980;308:331–351.
   PubMed Web of Science ®Google Scholar
• Ragueneau I, Laveille C, Jochemsen R, et al. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther. 1998;64(2):192–203.
   PubMed Web of Science ®Google Scholar
• Custodis F, Baumhakel M, Schlimmer N, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008;117(18):2377–2387.
   PubMed Web of Science ®Google Scholar
• Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817–823.
   PubMed Web of Science ®Google Scholar
• Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529–2536.
   PubMed Web of Science ®Google Scholar
• Werdan K, Ebelt H, Nuding S, et al. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol. 2012;101(5):365–373.
   PubMed Web of Science ®Google Scholar
• Koster R, Kaehler J, Meinertz T, et al. Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study. Am Heart J. 2009;158(4):e51–e57.
   Web of Science ®Google Scholar
• Tardif JC, Ponikowski P, Kahan T, et al. Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol. 2013;168(2):789–794.
   PubMed Web of Science ®Google Scholar
• Muller-Werdan U, Stockl G, Ebelt H, et al. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study. Exp Gerontol. 2014;59:34–41.
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091–1099.
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807–816.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–885.
   PubMed Web of Science ®Google Scholar
• Information, A.M. Ivabradine: highlights of prescribing information. Apr 2015.
   Google Scholar
• Mittal SR. Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of ivabradine, diltiazem and ranolazine. J Assoc Physicians India. 2014;62(5):426–427.
   PubMedGoogle Scholar
• Thadani U. Management of stable angina- current guidelines: a critical apraisal. Cardiovasc Drugs Ther. 2016; doi:10.1007/s10557-016-6681-2. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar